Ambar Protein Industries Limited has announced the approval of its unaudited financial results for the third quarter of fiscal year 2026, marking another milestone in the company's regulatory compliance and financial reporting process.

Board Meeting Outcomes

The company's Board of Directors convened on February 2, 2026, to deliberate on key financial matters. The meeting details and approvals are summarized below:

Key Approvals

During the board meeting, directors approved two critical documents essential for regulatory compliance and stakeholder transparency:

• Unaudited Financial Results: The board formally approved the financial results for the quarter and nine months ended December 31, 2025
• Limited Review Auditors' Report: Concurrent approval was granted for the auditors' limited review report on the unaudited financial results

Regulatory Compliance

The announcement was made in accordance with Regulation 33 requirements, demonstrating the company's commitment to maintaining transparent communication with stakeholders. The outcome was formally communicated to BSE Limited, where the company trades under scrip code 519471.

Company Information

Ambar Protein Industries Limited operates from its facility located at Plot No. 351, 353, 358, opposite Bhagyoday Hotel, Sarkhej-Bavla Highway, Changodar, in Ahmedabad district, Gujarat. The company is engaged in the refined cottonseed oil business and maintains its corporate identity under CIN L15400GJ1992PLC018758.

Ambar Protein Industries has witnessed multiple stake increases by its promoter through open market transactions in December. Minouli Pradeepbhai Khetani has made two separate acquisitions during the month, as disclosed under SEBI regulations.

Recent Transaction Details

The promoter's latest acquisition involved 2,488 equity shares representing 0.04% of the company's total share capital through open market transactions on December 19, 2025. This follows an earlier acquisition of 5,177 shares on December 9, 2025.

Shareholding Pattern Evolution

The cumulative acquisitions have resulted in a progressive increase in the promoter's total shareholding in the company. The promoter's stake has increased from 9.54% to 9.67% through these December transactions.

Company's Share Capital Structure

Ambar Protein Industries Limited maintains a consistent equity share capital structure throughout these transactions. The company's total equity share capital remains unchanged at ₹5.75 crores, consisting of 57,50,000 equity shares of ₹10 each.

The company's shares are listed on BSE Limited under scrip code 519471. The total diluted share capital also stands at ₹5.75 crores, consisting of 57,50,000 equity shares of ₹10 each, indicating no outstanding convertible securities or warrants.

Regulatory Compliance

Both disclosures were made in compliance with SEBI regulations governing substantial acquisition of shares and takeovers under Regulation 29(2). The promoter fulfilled the mandatory disclosure requirements by notifying both BSE Limited and the company about the transactions within the stipulated timeframe. This transparency ensures that all stakeholders are informed about changes in the promoter's shareholding pattern.